TP - Mold Illness Panel #1

There are no preparation instructions.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

ALPHA MELANOCYTE

COPEPTIN

Also known as: HLA Class II DR DQ DNA Typing

Hla-Dqb1*

Hla-Drb1*

TEST METHOD

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through a national lab. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The TP - Mold Illness Panel #1 panel contains 4 tests with 5 biomarkers.

The TP - Mold Illness Panel #1 comprises a series of tests each designed to evaluate specific markers or genetic predispositions that may indicate an individual's susceptibility to mold-related illnesses. Here is a detailed description of each test within the panel and the benefits of conducting these tests:

Test Name: Alpha Melanocyte Stimulating Hormone #91898

  • Description: This test measures the levels of alpha melanocyte stimulating hormone (α-MSH) in the blood, which is involved in inflammation regulation, immune response, and melanogenesis.
  • Purpose: The benefit of measuring α-MSH levels is to use it as an indicator of potential mold exposure and related health conditions. Elevated α-MSH levels can signal chronic inflammatory response syndrome (CIRS) and mold illness, aiding in the diagnosis and management of these conditions.

Test Name: Copeptin #37740

  • Description: This test assesses the concentration of copeptin in the blood, a fragment of the hormone vasopressin associated with stress responses, including those triggered by mold exposure.
  • Purpose: The main benefit is evaluating copeptin levels as a marker of HPA (hypothalamic-pituitary-adrenal) axis activation, which can indicate stress-related conditions and mold illness. This helps in understanding the stress response and guiding treatment strategies.

Test Name: HLA Class II DR, DQ DNA Typing #15485

  • Description: This genetic test looks at the variation in HLA class II genes DR and DQ to identify specific alleles associated with a higher risk of mold-related illnesses.
  • Purpose: Identifying HLA class II genetic variants linked to susceptibility to mold-related illnesses is beneficial for determining an individual's predisposition to adverse reactions following mold exposure. This knowledge can inform personalized preventive and treatment strategies.

Test Name: HLA DRB3,4,5 Low Resolution #19526

  • Description: Provides low-resolution typing of the HLA class II genes DRB3, DRB4, and DRB5, associated with immune dysregulation and increased susceptibility to mold-related illnesses.
  • Purpose: The benefit of this test is in determining genetic predispositions to mold-related health conditions through low-resolution typing of specific HLA class II genes. It aids in broader genetic screening to identify those at risk, guiding more targeted investigations or interventions.

Overall Purpose of the TP - Mold Illness Panel #1

The comprehensive evaluation offered by the TP - Mold Illness Panel #1 is beneficial in multiple ways:

  • Diagnostic Insight: It provides clinicians with a deeper understanding of an individual's physiological and genetic risk factors for mold-related illnesses, facilitating accurate diagnosis.
  • Personalized Medicine: Understanding the specific biomarkers and genetic predispositions of an individual allows for tailored treatment and prevention strategies, potentially improving outcomes.
  • Early Detection: Identifying susceptibility to mold-related illnesses before significant exposure or symptom development can lead to earlier interventions, reducing the impact of these conditions.

By offering a multi-faceted approach to understanding the impact of mold exposure on health, this panel serves as a crucial tool in the management and prevention of mold-related illnesses.

Customer Reviews